Clinical trial · Observational
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Tamoxifen Resistance in Breast Cancer
NCT00899197CI-TRIAL-00028893terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage IIIB breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gene expression analysis | Genetic | — | UNRESOLVED |
| immunoenzyme technique | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| protein expression analysis | Genetic | — | UNRESOLVED |
| tamoxifen citrate | Drug | Tamoxifen | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Evaluation of the mechanisms of tamoxifen citrate (TAM) resistance in breast cancer
- measure
- Change in expression levels of protein biomarkers of TAM resistance as measured periodically for 3 years or until relapse, whichever comes first
- measure
- Retrospective data on the predictive value of resistance-inducing genes
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed invasive breast cancer * Initial pathologic stage I-IIIB disease * No stage IV disease * Meets the following criteria for breast cancer therapy: * Received prior primary local therapy for breast cancer * Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within 3 weeks * Hormone receptor status: * Estrogen-receptor positive tumor * Female * Pre- or post-menopausal * Must be able to donate 20 mL of blood Exclusion Criteria: * Severe anemia, defined as hemoglobin \< 11 g/dL * Psychiatric history that would preclude obtaining informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.